Human AdV-20-42-42, a Promising Novel Adenoviral Vector for Gene Therapy and Vaccine Product Development

Preexisting immune responses toward adenoviral vectors limit the use of a vector based on particular serotypes and its clinical applicability for gene therapy and/or vaccination. Therefore, there is a significant interest in vectorizing novel adenoviral types that have low seroprevalence in the huma...

Descripción completa

Detalles Bibliográficos
Autores principales: Ballmann, Mónika Z., Raus, Svjetlana, Engelhart, Ruben, Kaján, Győző L., Beqqali, Abdelaziz, Hadoke, Patrick W. F., van der Zalm, Chantal, Papp, Tibor, John, Lijo, Khan, Selina, Boedhoe, Satish, Danskog, Katarina, Frängsmyr, Lars, Custers, Jerome, Bakker, Wilfried A. M., van der Schaar, Hilde M., Arnberg, Niklas, Lemckert, Angelique A. C., Havenga, Menzo, Baker, Andrew H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Microbiology 2021
Materias:
Gene Delivery
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8549523/
https://www.ncbi.nlm.nih.gov/pubmed/34469243
http://dx.doi.org/10.1128/JVI.00387-21

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8549523/
https://www.ncbi.nlm.nih.gov/pubmed/34469243
http://dx.doi.org/10.1128/JVI.00387-21

Ejemplares similares